FDA Outlines New Framework for Approving “Bespoke Therapies”
- November 14, 2025
The Food and Drug Administration (FDA) is pursuing a new approach for approving “bespoke therapies” for treating conditions so rare that randomized clinical trials may not be feasible.
ARTICLE TAGS
You must be logged in to access this content.